Recent advances in magnetoliposome for heart drug delivery

Abstract

Magnetic nanoparticles (NPs) also have been subject of interest to the therapeutic and imaging field because of their unique magnetic properties. Magnetoliposomes (MLs) are made up of a combination of liposomes and magnetic NPs, and they have been proven to be a potential biomaterial to fields like magnetic-targeted drug delivery, MRI, etc. The efficiency of a drug delivery system to the heart determines the treatment strategy for most of the heart diseases. In this review article, we summarize the recent development and updates in the application of MLs as a drug delivery system for heart/cardiac diseases.

Multi‐functional magnetic hydrogel: Design strategies and applications

“…Moreover, the hydrogels with electromagnetic effects can realize the above functions, while constructing electric microenvironment under external electrical stimulation to simulate directional tissue, guide cell proliferation and tissue regeneration. [69] On the other hand, magnetic scaffolds can control the biological behavior of cells through the magnetic response between MNPs and magnetic field [70] ; thus, promoting revascularization, cartilage/bone regeneration, [71] neuroregulation, [72] and wound repair. [67] Carlo et al described a 3D magnetic hyaluronic hydrogel that provides non-invasive neuromodulation by magneto-mechanically stimulating primary dorsal root ganglion (DRG) neurons (Figure 7B).…”

Nanoparticle-Mediated Drug Delivery for Treatment of Ischemic Heart Disease

“…Magnetoliposomes (MLs) are composed of liposomes and magnetic NPs and are the first efficient hybrid liposome/NP systems produced for the drug delivery ( Namdari et al, 2017 ). In this line, several experimental strategies have been investigated the potential scope of magnetic NPs to leverage the delivery of growth factors, cytokines, and biomolecules to the degenerating cardiac cells and tissues and enhance their regeneration ( Allen and Cullis, 2013 ; Paul et al, 2014 ; Ottersbach et al, 2018 ).…”

“…Hybrid organic-inorganic NPs hold great promise in overcoming the pitfalls being faced by existing inorganic materials in the delivery of therapeutics and contrast agents (Somasuntharam et al, 2016), such as unwanted interactions with serum proteins (particularly opsonins) and consequential removal from the circulation by macrophages of mononuclear phagocytic system, rapid renal clearance, prolonged body accumulation, and lack of targetability (Zhou and Zhang, 2019). Magnetoliposomes (MLs) are composed of liposomes and magnetic NPs and are the first efficient hybrid liposome/NP systems produced for the drug delivery (Namdari et al, 2017). In this line, several experimental strategies have been investigated the potential scope of magnetic NPs to leverage the delivery of growth factors, cytokines, and biomolecules to the degenerating cardiac cells and tissues and enhance their regeneration (Allen and Cullis, 2013;Paul et al, 2014;Ottersbach et al, 2018).…”

Recent developments in the use of organic–inorganic nanohybrids for drug delivery

“…Furthermore, liposomes (Namdari, Cheraghi, Negahdari, Eatemadi, & Daraee, ; K. Yang et al, ), peptides (Kumar et al, ; Vinzant et al, ), dendrimers (Ray et al, ), and graphene oxide (GO) are among the other organic systems that have been used to create iron oxide organic nanohybrids (IOONH) nanohybrids for drug delivery recently. In the work carried out by Lerra et al (), site‐specific DOX delivery to neuroblastoma cells has been achieved using a IOONH containing GO.…”